4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Palisade Bio, Inc. (PALI) operates in the Biotechnology industry and is headquartered in Denver, United States with about 14 employees. Its market capitalization is roughly $202 million. In the fiscal year ended 2025-12-31, PALI reported $0M in revenue and ($17M) in net income.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.
Interactive charts & full statements → Open the PALI valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($35M) | ($18M) | ($15M) | ($13M) | ($16M) | — |
| Net Income | ($32M) | ($17M) | ($14M) | ($12M) | ($14M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($12M) | ($11M) | ($10M) | ($3M) | ($3M) | — |
| Net Income | ($11M) | ($10M) | ($9M) | ($3M) | ($3M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $134M | $11M | $14M | $16M | — |
| Total Liabilities | $5M | $3M | $3M | $3M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PALI viewer.
About TickerBase · Data methodology & sources · Privacy · Terms